Idylla EGFR Lung Trial
- Conditions
- TechnologyOncologyLung Cancer
- Registration Number
- NCT04962191
- Lead Sponsor
- Anthony Magliocco
- Brief Summary
This retrospective, observational study will compare the results of a BioCartis' EGFR mutation test on the Idylla platform with test results from SoC pathology results from tissue biopsies in the same setting. A comparable rapid testing platform for EGFR may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies. Up to 150 samples will be tested and compared with existing results.
- Detailed Description
This study will compare the results of a BioCartis' EGFR mutation test on theIdylla platform with test results from standard of care (SoC) pathology results from tissue biopsies. The Idylla™ EGFR Mutation Test, performed on the BioCartis Idylla™ System, is an in vitro diagnostic test for the qualitative detection of exon 18, exon 20, and exon 21 mutations. Additionally, exon 19 deletions and exon 20 insertions in the EGFR oncogene. A rapid testing platform for EGFR may serve as a more accessible means to diagnose, and overall, more patients treated successfully with targeted therapies.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
- Patients diagnosed with primary lung cancer
- Data from primary diagnosis must be included in pathology report or data entry.
- Detailed pathology report included for all samples
- Limited or no tissue available
- Only tissue available is from fine needle aspiration
- Tissue blocks older than 5 years old
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Idylla EGFR Mutation Test Retrospective tissue samples no longer than 5 years old The primary outcome measured is if the Idylla EGFR Mutation Test is a possible alternative to diagnose EGFR mutation status in tissue samples.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
6555 Sanger Rd, Suite 260
🇺🇸Orlando, Florida, United States
6555 Sanger Rd, Suite 260🇺🇸Orlando, Florida, United StatesHannah Park, BSContact754-242-9682hannah.park@proteanbiodx.comSo Hyeon Park, MSContact754-242-9682sohyeon.park@proteanbiodx.comAnthony Magliocco, MDPrincipal Investigator